{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:10:18Z","timestamp":1793938218401,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48602-3","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:55:25Z","timestamp":1776351325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Foslevodopa\u2013Foscarbidopa subcutaneous infusion in Parkinson\u2019s disease: a cross-cultural\/cross-racial international multicentre comparative tolerability study (CRIM-FOS study)"],"prefix":"10.1038","volume":"16","author":[{"given":"Vinod","family":"Metta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Poplawska-Domaszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Brek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsal","family":"Nalarakettil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Masagnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Sangilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elmahdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallol Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"48602_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","volume":"14","author":"A Reeve","year":"2014","unstructured":"Reeve, A., Simcox, E. & Turnbull, D. Ageing and Parkinson\u2019s disease: Why is advancing age the biggest risk factor? Ageing Res. Rev. 14, 19\u201330 (2014). [CrossRef].","journal-title":"Ageing Res. Rev."},{"key":"48602_CR2","unstructured":"Parkinson\u2019s Foundation. Statistics. Available online: https:\/\/www.parkinson.org\/Understanding-Parkinsons\/Statistics (accessed on 25 October 2019)."},{"issue":"3\u20134","key":"48602_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000442283","volume":"74","author":"Y Alamri","year":"2015","unstructured":"Alamri, Y., MacAskill, M., Anderson, T. & Benamer, H. Parkinson\u2019s disease in the gulf countries: An updated review. Eur. Neurol. 74 (3\u20134), 222\u2013225. https:\/\/doi.org\/10.1159\/000442283 (2015). Epub 2015 Nov 28. PMID: 26613525.","journal-title":"Eur. Neurol."},{"issue":"8","key":"48602_CR4","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/jpm12081300","volume":"12","author":"V Metta","year":"2022","unstructured":"Metta, V. et al. First two-year observational exploratory real life clinical phenotyping, and societal impact study of Parkinson\u2019s disease in emiratis and expatriate population of United Arab Emirates 2019\u2013202: The EmPark Study. J. Pers. Med. 12 (8), 1300. https:\/\/doi.org\/10.3390\/jpm12081300 (2022). PMID: 36013249; PMCID: PMC9410099.","journal-title":"J. Pers. Med."},{"key":"48602_CR5","doi-asserted-by":"publisher","first-page":"1365339","DOI":"10.3389\/fneur.2024.1365339","volume":"15","author":"AA Alokley","year":"2024","unstructured":"Alokley, A. A. et al. Assessing the perception of Parkinson\u2019s disease in Al-Ahsa, Saudi Arabia among the visitors of a public campaign: before and after survey. Front. Neurol. 15, 1365339 (2024). PMID: 38633531; PMCID: PMC11021784.","journal-title":"Front. Neurol."},{"issue":"1","key":"48602_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser, R. A. Levodopa: past, present, and future. Eur. Neurol. 62 (1), 1\u20138 (2009).","journal-title":"Eur. Neurol."},{"issue":"8","key":"48602_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 5 (8), 677\u2013687 (2006).","journal-title":"Lancet Neurol."},{"key":"48602_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mds.27386","volume":"33","author":"K Ray Chaudhuri","year":"2018","unstructured":"Ray Chaudhuri, K., Poewe, W. & Brooks, D. Motor and nonmotor complications of levodopa: Phenomenology, risk factors, and imaging features. Mov. Disord Off J. Mov. Disord Soc. 33, 909\u2013919 (2018). [CrossRef] [PubMed].","journal-title":"Mov. Disord Off J. Mov. Disord Soc."},{"key":"48602_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/14740338.2019.1681966","volume":"18","author":"V Leta","year":"2019","unstructured":"Leta, V., Jenner, P., Chaudhuri, K. R. & Antonini, A. Can therapeutic strategies prevent and manage dyskinesia in Parkinson\u2019s disease? An update. Expert Opin. Drug Saf. 18, 1203\u20131218 (2019). [CrossRef] [PubMed].","journal-title":"Expert Opin. Drug Saf."},{"key":"48602_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L. & Durif, F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov. Disord Off J. Mov. Disord Soc. 20, 224\u2013230 (2005). [CrossRef] [PubMed].","journal-title":"Mov. Disord Off J. Mov. Disord Soc."},{"key":"48602_CR11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis, M. et al. Parkinson\u2019s disease symptoms: The patient\u2019s perspective. Mov. Disord Off J. Mov. Disord Soc. 25, 1646\u20131651 (2010). [CrossRef] [PubMed].","journal-title":"Mov. Disord Off J. Mov. Disord Soc."},{"key":"48602_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.disamonth.2007.02.004","volume":"53","author":"JS Dubow","year":"2007","unstructured":"Dubow, J. S. Autonomic dysfunction in Parkinson\u2019s disease. Dis. Mon. 53, 265\u2013274 (2007). [CrossRef] [PubMed].","journal-title":"Dis. Mon"},{"issue":"Suppl. 2","key":"48602_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/00207454.2011.620196","volume":"121","author":"M Stacy","year":"2011","unstructured":"Stacy, M. Nonmotor symptoms in Parkinson\u2019s disease. Int. J. Neurosci. 121 (Suppl. 2), 9\u201317 (2011). [CrossRef] [PubMed].","journal-title":"Int. J. Neurosci."},{"key":"48602_CR14","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: Results from an international pilot study. Mov. Disord. 22, 1901\u20131911 (2007). [CrossRef] [PubMed].","journal-title":"Mov. Disord"},{"key":"48602_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri, K. R. & Schapira, A. H. Non-motor symptoms of Parkinson\u2019s disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 8, 464\u2013474 (2009). [CrossRef].","journal-title":"Lancet Neurol."},{"key":"48602_CR16","first-page":"89","volume-title":"The Scientific Basis for the Treatment of Parkinson\u2019s Disease","author":"S Fahn","year":"1992","unstructured":"Fahn, S. Adverse effects of levodopa. In The Scientific Basis for the Treatment of Parkinson\u2019s Disease; (eds Olanow, C. W. & Lieberman, A. N.) Parthenon Publishing Group: Carnforth, UK, ; 89\u2013112. (1992)."},{"issue":"Suppl. 1","key":"48602_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1017\/S0317167100046412","volume":"11","author":"S Fahn","year":"1984","unstructured":"Fahn, S. & Bressman, S. B. Should levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment. Can. J. Neurol. Sci. J. Can. Des. Sci. Neurol. 11 (Suppl. 1), 200\u2013205 (1984). [CrossRef] [PubMed].","journal-title":"Can. J. Neurol. Sci. J. Can. Des. Sci. Neurol."},{"key":"48602_CR18","first-page":"153","volume-title":"Recent Developments in Parkinson\u2019s Disease","author":"S Fahn","year":"1987","unstructured":"Fahn, S. & Elton, R. L. Members of the UPDRS Development Committee. Unified Parkinson\u2019s disease rating scale. in Recent Developments in Parkinson\u2019s Disease (eds Fahn, S., Marsden, C. D., Calne, D. B. & Goldstein, M.) Vol. 2, 153\u2013163 (MacMillan Healthcare Information, Florham Park, NJ, USA, 1987)."},{"issue":"21 Suppl 4","key":"48602_CR19","first-page":"S1","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow, C. W., Stern, M. B. & Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72 (21 Suppl 4), S1\u2013136 (2009).","journal-title":"Neurology"},{"issue":"1\u20132","key":"48602_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2009.08.053","volume":"289","author":"D Grosset","year":"2010","unstructured":"Grosset, D. Therapy adherence issues in Parkinson\u2019s disease. J. Neurol. Sci. 289 (1\u20132), 115\u2013118 (2010).","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"48602_CR21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","volume":"30","author":"K Johnell","year":"2007","unstructured":"Johnell, K. & Klarin, I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 30 (10), 911\u2013918 (2007).","journal-title":"Drug Saf."},{"issue":"1","key":"48602_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","volume":"29","author":"N Malek","year":"2015","unstructured":"Malek, N. & Grosset, D. G. Medication adherence in patients with Parkinson\u2019s disease. CNS Drugs. 29 (1), 47\u201353 (2015).","journal-title":"CNS Drugs"},{"issue":"1","key":"48602_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00702-023-02700-y","volume":"131","author":"V Metta","year":"2024","unstructured":"Metta, V. et al. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson\u2019s disease based in United Arab Emirates. J. Neural Transm (Vienna). 131 (1), 25\u201330. https:\/\/doi.org\/10.1007\/s00702-023-02700-y (2024). Epub 2023 Oct 5. PMID: 37798410; PMCID: PMC10769978.","journal-title":"J. Neural Transm (Vienna)"},{"issue":"1","key":"48602_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano, A. et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 19 (1), 50. https:\/\/doi.org\/10.1186\/s12883-019-1276-8 (2019). PMID: 30940119; PMCID: PMC6444751.","journal-title":"BMC Neurol."},{"key":"48602_CR25","doi-asserted-by":"publisher","first-page":"7537924","DOI":"10.1155\/2020\/7537924","volume":"2020","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda, D., de Deus Fonticoba, T., Su\u00e1rez Castro, E., Aneiros D\u00edaz, A. & McAfee, D. 5-2-1 Criteria: A simple screening tool for identifying advanced pd patients who need an optimization of Parkinson\u2019s treatment. Parkinsons Dis. 2020, 7537924. https:\/\/doi.org\/10.1155\/2020\/7537924 (2020). PMID: 32269748; PMCID: PMC7128051.","journal-title":"Parkinsons Dis."},{"issue":"7","key":"48602_CR26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/jpm11070680","volume":"11","author":"V Metta","year":"2021","unstructured":"Metta, V. et al. Parkinson\u2019s disease: personalized pathway of care for device-aided therapies (DAT) and the role of continuous objective monitoring (COM) using wearable sensors. J. Pers. Med. 11 (7), 680. https:\/\/doi.org\/10.3390\/jpm11070680 (2021). PMID: 34357147; PMCID: PMC8305099.","journal-title":"J. Pers. Med."},{"issue":"21 Suppl 4","key":"48602_CR27","first-page":"S1","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow, C. W., Stern, M. B. & Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72 (21 Suppl 4), S1\u2013136 (2009).","journal-title":"Neurology"},{"key":"48602_CR28","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"G Deuschl","year":"2022","unstructured":"Deuschl, G. et al. European academy of neurology\/movement disorder society\u2014European section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Eur. J. Neurol. 29, 2580\u20132595 (2022).","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"48602_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mdc3.12988","volume":"7","author":"T Henriksen","year":"2020","unstructured":"Henriksen, T. et al. Access and use of device-aided therapies for Parkinson\u2019s disease in Denmark. Mov. Disord Clin. Pract. 7 (6), 656\u2013663 (2020).","journal-title":"Mov. Disord Clin. Pract."},{"issue":"9","key":"48602_CR30","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","volume":"40","author":"E Olivola","year":"2019","unstructured":"Olivola, E. et al. Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: causes of discontinuation and subsequent treatment strategies. Neurol. Sci. 40 (9), 1917\u20131923 (2019).","journal-title":"Neurol. Sci."},{"issue":"2","key":"48602_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser, R. A. et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. 23 (2), 75\u201381 (2000).","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"48602_CR32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3233\/JPD-212813","volume":"11","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh, M., Liu, W., Neenan, M. & Facheris, M. F. Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J. Parkinsons Dis. 11 (4), 1695\u20131702 (2021).","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"48602_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh, M. et al. Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann. Neurol. 90 (1), 52 (2021).","journal-title":"Ann. Neurol."},{"issue":"8","key":"48602_CR34","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/jpm12081300","volume":"12","author":"V Metta","year":"2022","unstructured":"Metta, V. et al. First two-year observational exploratory real life clinical phenotyping, and societal impact study of Parkinson\u2019s disease in emiratis and expatriate population of United Arab Emirates 2019\u20132021: The EmPark Study. J. Pers. Med. 12 (8), 1300. https:\/\/doi.org\/10.3390\/jpm12081300 (2022). PMID: 36013249; PMCID: PMC9410099.","journal-title":"J. Pers. Med."},{"issue":"3","key":"48602_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jsmc.2025.06.006","volume":"20","author":"V Metta","year":"2025","unstructured":"Metta, V., Pop\u0142awska-Domaszewicz, K., Chen, R. & Chaudhuri, K. R. Clinical personalized medicine for Parkinson\u2019s disease and implications on sleep dysfunction. Sleep. Med. Clin. 20 (3), 417\u2013422. https:\/\/doi.org\/10.1016\/j.jsmc.2025.06.006 (2025). Epub 2025 Jul 8. PMID: 40912754.","journal-title":"Sleep. Med. Clin."},{"key":"48602_CR36","unstructured":"UK Government. List of ethnic groups. Ethnicity Facts and Figures [Internet]. London: UK Government; [cited 2025 December 30]. Available from: https:\/\/www.ethnicity-facts-figures.service.gov.uk\/style-guide\/ethnic-groups\/"},{"issue":"4","key":"48602_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5603\/pjnns.99624","volume":"58","author":"K Duda","year":"2024","unstructured":"Duda, K., Chmiela, T., Cie\u015bla-Fu\u0142awka, A., Gawryluk, J. & Siuda, J. Are 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson\u2019s Disease? Neurol. Neurochir. Pol. 58 (4), 422\u2013428. https:\/\/doi.org\/10.5603\/pjnns.99624 (2024). Epub 2024 Jul 5. PMID: 38967144.","journal-title":"Neurol. Neurochir. Pol."},{"key":"48602_CR38","doi-asserted-by":"publisher","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 30 (12), 1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424 (2015). PMID: 26474316.","DOI":"10.1002\/mds.26424"},{"key":"48602_CR39","doi-asserted-by":"publisher","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 25 (15), 2649\u201353. https:\/\/doi.org\/10.1002\/mds.23429 (2010). PMID: 21069833.","DOI":"10.1002\/mds.23429"},{"issue":"2","key":"48602_CR40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1212\/WNL.50.2.318","volume":"50","author":"MM Hoehn","year":"1998","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression, and mortality. Neurology 50 (2), 318 (1998).","journal-title":"Neurology"},{"key":"48602_CR41","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Mart\u00edn, P. et al. Unified Parkinson\u2019s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 9 (1), 76\u201383. https:\/\/doi.org\/10.1002\/mds.870090112 (1994). PMID: 8139608.","DOI":"10.1002\/mds.870090112"},{"key":"48602_CR42","doi-asserted-by":"publisher","unstructured":"Chaudhuri, K. R. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 21 (7), 916\u201323. https:\/\/doi.org\/10.1002\/mds.20844 (2006). PMID: 16547944.","DOI":"10.1002\/mds.20844"},{"key":"48602_CR43","doi-asserted-by":"publisher","unstructured":"Johns, M. W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 14 (6), 540\u2212505. https:\/\/doi.org\/10.1093\/sleep\/14.6.540 (1991). PMID: 1798888.","DOI":"10.1093\/sleep\/14.6.540"},{"issue":"4","key":"48602_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder, C. et al. Parkinson\u2019s disease sleep scale\u2013validation of the revised version PDSS 2. Mov. Disord. 26 (4), 644\u2013652. https:\/\/doi.org\/10.1002\/mds.23476 (2011). Epub 2011 Feb 10. PMID: 21312275.","journal-title":"Mov. Disord"},{"issue":"6","key":"48602_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/08870449708406741","volume":"12","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The PDQ-8: development and validation of a short-form Parkinson\u2019s disease questionnaire. Psychol. Health. 12 (6), 805\u2013814. https:\/\/doi.org\/10.1080\/08870449708406741 (1997).","journal-title":"Psychol. Health"},{"key":"48602_CR46","doi-asserted-by":"publisher","unstructured":"Grat\u00e3o, A. C. M. et al. Brief version of Zarit Burden Interview (ZBI) for burden assessment in older caregivers. Dement. Neuropsychol. 13 (1), 122\u2013129. https:\/\/doi.org\/10.1590\/1980-57642018dn13-010015 (2019). PMID: 31073389; PMCID: PMC6497029.","DOI":"10.1590\/1980-57642018dn13-010015"},{"key":"48602_CR47","doi-asserted-by":"publisher","unstructured":"Chaudhuri, K. R. et al. EUROPAR and the IPMDS non-motor PD Study group. King\u2019s Parkinson\u2019s Disease pain scale (KPPS): Development and international validation, the first scale for pain in Parkinson\u2019s disease. Mov. Disord. 30 (12), 1623\u20131631. https:\/\/doi.org\/10.1002\/mds.26270 (2015).","DOI":"10.1002\/mds.26270"},{"key":"48602_CR48","doi-asserted-by":"publisher","unstructured":"Thakur, N., Lovinsky-Desir, S., Appell, D., Bime, C., Castro, L., Celedon, J., Ferreira, J., George, M., Mageto, A. Y., III, Pakhale, S., Riekert, K., Roman, J., Ruvalcaba, E., Sharma, S., Shete, P., Wisnivesky, J., Holguin, F. Enhancing recruitment and retention of minority populations for clinical research in pulmonary, critical care, and sleep medicine: An official american thoracic society research statement. Am. J. Respiratory Critic. Care Med. 204, e26\u2013e50. https:\/\/doi.org\/10.1164\/rccm.202105-1210ST (2021).","DOI":"10.1164\/rccm.202105-1210ST"},{"issue":"3","key":"48602_CR49","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JPD-213113","volume":"12","author":"YH Lau","year":"2022","unstructured":"Lau, Y. H. et al. Does ethnicity influence recruitment into clinical trials of Parkinson\u2019s disease? J. Parkinson\u2019s Disease. 12 (3), 975\u2013981. https:\/\/doi.org\/10.3233\/JPD-213113 (2022).","journal-title":"J. Parkinson\u2019s Disease"},{"key":"48602_CR50","doi-asserted-by":"publisher","first-page":"107092","DOI":"10.1016\/j.cct.2023.107092","volume":"126","author":"S Versavel","year":"2023","unstructured":"Versavel, S. et al. Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor. Contemp. Clin. Trials. 126, 107092. https:\/\/doi.org\/10.1016\/j.cct.2023.107092 (2023).","journal-title":"Contemp. Clin. Trials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48602-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48602-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48602-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:37:33Z","timestamp":1780958253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48602-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48602-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17728"}}